Company Analysis

ADC Therapeutics SA (ADCT)

NYSE: ADCT · Pharmaceutical Preparations · Epalinges, CH · filing with the SEC since 2019
Grade5.3
◀ Past 5.5● Present 4.8▶ Future 6.0
2 est.

Who owns ADC Therapeutics SA

As filed with the SEC
Holders of 5% or more
4
Nantahala Capital Management, LLC holds 9.69% of Common Shares, par value CHF 0.08 per share, as its SCHEDULE 13G filed Aug 14, 2026 says.
Directors and officers
12
report now, of 14 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Nantahala Capital Management, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Shares, par value CHF 0.08 per share
9.69%
TCG Crossover GP II, LLC
SCHEDULE 13G · filed Feb 17, 2026 · Common Shares, par value CHF $0.08 per share
9.2%
Prosight Management, LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Shares · 5.8% in Nov 13, 2025
6.8%
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock · 5% in Apr 24, 2025
5.4%
Redmile Group, LLC
SCHEDULE 13G/A · filed Apr 24, 2026 · Common Shares, par value CHF 0.08 per share · reported falling below 5%, from 9.9% in Apr 6, 2026
under 5%
Dr. Hans-Peter Wild
SCHEDULE 13G/A · filed May 19, 2025 · Common Shares, par value CHF 0.08 per share · reported falling below 5%
under 5%
Oaktree Fund Administration, LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · Common Shares · reported falling below 5%
under 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Shares, par value CHF 0.08 per share · reported falling below 5%, from 7% in Jun 17, 2025
under 5%
Orbimed Capital LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Shares, par value CHF 0.08 per share · reported falling below 5%, from 3.6% in Feb 14, 2025
under 5%
What ADCT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Overland ADCT BioPharma (CY) Limited
An investee · investee · invested in, named in the 10-K filed Mar 10, 2026

2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 10, 2026.

Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
24
2024 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 18 on the roster
PersonRole as filedSalesSoldOn a planBuysBought
Redco II Master Fund, L.P.10% owner6$19.6M00$0
SI Assistanton ADCT · research, not advice